NPPB and cardiac amyloidosis: In summary, the future management of cardiac amyloidosis is likely to be a multidimensional approach, where haematological, NT-proBNP response and CMR response will have a different role at different time points and the combination of these markers will depict a comprehensive clinical picture that could help clinicians to better tailor chemotherapy treatment in each individual patient.